Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Nhwa Pharmaceutical Co., Ltd. (002262.SZ)
CNY21.25
+0.68 (+3.31%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
69 South Minzhu Road 221009
Xuzhou, CN
Xuzhou, CN
CEO
Jiaquan Sun
Website
nhwa-group.com
IPO
2008-07-15
ISIN CNE100000CG8
Description
Jiangsu Nhwa Pharmaceutical Co., LTD operates as a global pharmaceutical entity, focusing on the research, production, and sale of treatments for the central nervous system, along with cardiovascular and cerebrovascular ailments. Its comprehensive product line includes therapeutics for anesthesia, psychiatry, and neurological disorders. Additionally, the company is a supplier of Active Pharmaceutical Ingredients (APIs), specifically for central nervous system, anesthetic, and sedative applications, among others. The firm was established in 1978 and is based in Xuzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY21.25
+0.68 (+3.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
-0.21
Float Shares
515.03M
Free Float %
50.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.84% | -1.41% | -9.46% | -14.78% | -16.74% | -15.91% | -13.36% | -35.20% | +29.32% | +81.81% | +597.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
21.25
DCF (Unlevered)
39.74
+87.0%
DCF (Levered)
40.10
+88.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
12.28
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.7% Q1'26: +6.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-7.1% Q1'26: +3.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+13.1% Q1'26: +5.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.7% ★ Q1'26: +20.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+21.9% ★ Q1'26: +25.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.3% ★ Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.41× ★ Q1'26: 0.30× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.77B
est: 2.78B (-0.5%)
|
3.02B
est: 3.02B (0.0%)
|
3.39B
est: 3.41B (-0.3%)
|
3.86B
est: 3.83B (+0.7%)
|
4.15B
est: 4.19B (-0.9%)
|
3.36B
est: 3.38B (-0.4%)
|
3.94B
est: 3.87B (+1.8%)
|
4.30B
est: 4.32B (-0.6%)
|
5.04B
est: 5.09B (-1.0%)
|
5.70B
est: 5.85B (-2.6%)
|
5.85B
est: 6.24B (-6.2%)
|
6.44B
6.24B – 6.64B
+3.3% YoY
|
7.12B
6.40B – 7.77B
+10.6% YoY
|
7.86B
7.33B – 8.36B
+10.4% YoY
|
| EBITDA |
355.51M
est: 679.52M (-47.7%)
|
393.07M
est: 737.55M (-46.7%)
|
455.29M
est: 832.28M (-45.3%)
|
646.09M
est: 936.37M (-31.0%)
|
776.16M
est: 1.02B (-24.2%)
|
878.36M
est: 825.17M (+6.4%)
|
959.57M
est: 944.91M (+1.6%)
|
1.02B
est: 1.06B (-3.0%)
|
1.20B
est: 1.24B (-3.2%)
|
1.36B
est: 1.34B (+1.6%)
|
1.10B
est: 1.43B (-23.5%)
|
1.48B
1.43B – 1.52B
+3.3% YoY
|
1.64B
1.47B – 1.78B
+10.6% YoY
|
1.81B
1.68B – 1.92B
+10.4% YoY
|
| EBIT |
305.93M
est: 602.05M (-49.2%)
|
341.79M
est: 653.46M (-47.7%)
|
394.65M
est: 737.39M (-46.5%)
|
566.01M
est: 829.62M (-31.8%)
|
688.01M
est: 906.79M (-24.1%)
|
781.53M
est: 731.09M (+6.9%)
|
847.28M
est: 837.18M (+1.2%)
|
901.63M
est: 936.00M (-3.7%)
|
1.07B
est: 1.10B (-3.0%)
|
1.21B
est: 1.21B (+0.0%)
|
1.10B
est: 1.29B (-15.4%)
|
1.34B
1.29B – 1.38B
+3.3% YoY
|
1.48B
1.33B – 1.61B
+10.6% YoY
|
1.63B
1.52B – 1.73B
+10.4% YoY
|
| Net Income |
258.35M
est: 266.66M (-3.1%)
|
309.74M
est: 325.49M (-4.8%)
|
394.63M
est: 398.36M (-0.9%)
|
524.81M
est: 480.88M (+9.1%)
|
663.31M
est: 652.74M (+1.6%)
|
728.82M
est: 750.91M (-2.9%)
|
797.78M
est: 846.04M (-5.7%)
|
900.71M
est: 900.68M (+0.0%)
|
1.04B
est: 1.09B (-5.0%)
|
1.14B
est: 1.21B (-5.1%)
|
1.06B
est: 1.43B (-26.2%)
|
1.16B
1.06B – 1.26B
-19.0% YoY
|
1.29B
1.16B – 1.42B
+11.6% YoY
|
1.45B
1.32B – 1.57B
+11.9% YoY
|
| SGA |
806.39M
est: 1.16B (-30.3%)
|
990.91M
est: 1.26B (-21.1%)
|
1.06B
est: 1.42B (-25.1%)
|
1.35B
est: 1.59B (-15.7%)
|
1.65B
est: 1.74B (-5.3%)
|
1.44B
est: 1.41B (+2.7%)
|
1.74B
est: 1.61B (+8.3%)
|
1.85B
est: 1.80B (+2.7%)
|
1.94B
est: 2.12B (-8.3%)
|
2.24B
est: 2.39B (-6.0%)
|
2.27B
est: 2.54B (-10.8%)
|
2.63B
2.55B – 2.71B
+3.3% YoY
|
2.91B
2.61B – 3.17B
+10.6% YoY
|
3.21B
2.99B – 3.41B
+10.4% YoY
|
| EPS |
0.26
est: 0.26 (-1.3%)
|
0.31
est: 0.32 (-3.6%)
|
0.39
est: 0.39 (-0.9%)
|
0.52
est: 0.48 (+9.4%)
|
0.66
est: 0.65 (+2.3%)
|
0.72
est: 0.74 (-3.0%)
|
0.79
est: 0.84 (-5.5%)
|
0.89
est: 0.89 (+0.0%)
|
1.03
est: 1.08 (-4.5%)
|
1.13
est: 1.20 (-5.4%)
|
1.05
est: 1.42 (-26.1%)
|
1.15
1.05 – 1.24
-19.0% YoY
|
1.28
1.15 – 1.41
+11.6% YoY
|
1.44
1.31 – 1.56
+11.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
547.79M
OE per share TTM
0.54
Owner's Yield
2.67%
Maintenance CapEx ratio
16.31%
Maint CapEx / Avg PPE
28.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 31 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.10% | 37.9K | 0.65% |
| 2 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.03% | 19.1K | 0.55% |
| 3 | State Street SPDR S&P China ETF GXC | 0.02% | 68.2K | 0.59% |
| 4 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 8.6K | 0.15% |
| 5 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 164.0K | 0.19% |
| 6 | Franklin FTSE China ETF FLCH | 0.01% | 19.4K | 0.19% |
| 7 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 276.7K | 0.06% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 177.5K | 0.29% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 24.5K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 55.2K | 0.26% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
184.9K
Shares Outstanding
1.02B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bao Zhou Duan | Deputy GM & Secretary | — | male |
| Gangsheng Li | Chief Financial Officer | — | male |
| Ji Rui Hu | Accounting Supervisor | — | — |
| Jiaquan Sun | GM & Non-Independent Director | — | male |
| Qing Fu | Deputy GM & Non-Independent Director | — | male |
| Zengliang Chen | Deputy GM & Non-Independent Director | — | male |
| Ziliang Yang | Deputy GM & Non-Independent Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002262.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
